ClinicalTrials.gg
TerminatedNCT04601103Updated Oct 1, 2024Results posted

3M Oral Rinse Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpastes

An interventional study of No SLS toothpaste and Medium SLS toothpaste in Oral Mucosal Disorder, sponsored by Solventum US LLC. Terminated at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Solventum US LLC · Not applicable, Interventional, and Basic science

Why this study was terminated
Device Deficiency

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2020, registered Oct 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the incidence of oral tissue sloughing through self-report by study subjects and by professional dental examinations.

Read the detailed description

The primary objective of this study is to evaluate the incidence of oral tissue sloughing through self-report by study subjects and by professional dental examinations. Adverse events will be tracked through study dental examinations and subject diaries with twice daily use of the 3M Oral Rinse used in combination with toothpaste containing one of three levels (no, medium, high) of Sodium Lauryl Sulfate (SLS).

Determine the subjects' acceptance of sloughing and/or other side effects

02

Conditions studied

  • Oral Mucosal Disorder
03

In context

Lead sponsor

Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and willing to sign the ;
  2. Willing to agree to maintain confidentiality of the study and study materials;
  3. 3M employee aged 18 years and older;
  4. Willing to return to the study facility for scheduled study visits and recalls;
  5. Agree not to use other oral hygiene products (non-study toothpaste, non-study toothbrush, mouth rinse, chewing gum);
  6. Agree to the study instruction and schedule

Exclusion criteria

Exclusion Criteria:

  1. A member of the Medical Clinical Affairs (MCA) staff or Panda product team for the device under investigation;
  2. Have a dental appointment scheduled during study duration for professional cleaning;
  3. Is pregnant, nursing, or planning to become pregnant within the study duration;
  4. History of antibiotic therapy within the previous 30 days or have a condition that is likely to need antibiotic treatment over the course of the study (e.g., cardiac conditions requiring antibiotic prophylaxis such as heart murmurs, pacemakers, or prosthetic heart valves and prosthetic implants);
  5. History of using a prescription antimicrobial mouth rinse during the past 3 months;
  6. Currently taking medications which may alter gingival appearance/bleeding;
  7. Currently using anticonvulsants, calcium channel blockers, or other medications with side effects known to impact oral health;
  8. Participation in any other clinical study within the last 30 days;
  9. Resides in the same household with a subject already enrolled in the study;
  10. Known history of sensitivity to oral hygiene products;
  11. Currently using tobacco products (cigarettes, chewing tobacco) or vaping products (ecigarettes);
  12. History of diabetes;
  13. Have removable partial/full dentures;
  14. Have orthodontic appliances;
  15. Have medical or oral conditions that may compromise the subject's safety or interfere with the conduct and outcome of the study;
  16. Have known sloughing within the last 3 weeks;
  17. Have dry mouth;
  18. Have widespread caries or chronic neglect;
  19. Have gross pathological changes of oral soft tissues;
  20. Have advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive alveolar bone loss);
  21. Unsuitable for enrollment in this study based on the professional opinion of the dental examiner based on the oral exam or other reasons not specified in the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Comparator: No SLS Toothpaste

    3M Oral Rinse in combination with no SLS toothpaste (A)

    Drug: No SLS toothpaste · Device: Anti-plaque

  • Experimental
    Comparator: Medium SLS Toothpaste

    3M Oral Rinse in combination with medium SLS toothpaste (B)

    Drug: Medium SLS toothpaste · Device: Anti-plaque

  • Experimental
    Comparator: High SLS Toothpaste

    3M Oral Rinse in combination with high SLS toothpaste (C)

    Drug: High SLS toothpaste · Device: Anti-plaque

Interventions

  • DrugNo SLS toothpaste

    Toothpaste no Sodium Lauryl Sulfate

    Also known as: Sensodyne ProNamel Fresh Breath Toothpaste

  • DrugMedium SLS toothpaste

    Less than or equal to X ppm Sodium Lauryl Sulfate

    Also known as: Clinpro Tooth Creme

  • More than or equal to X ppm Sodium Lauryl Sulfate

    Also known as: Colgate Cavity Protection Toothpaste

  • DeviceAnti-plaque

    Rinse prevents bacterial adherence to teeth

    Also known as: 3M Oral Rinse

06

What researchers measure

Primary outcomes

  1. Number of Participants With Oral Mucosal Exfoliation (Oral Sloughing)

    Percentage of participants who experienced oral sloughing as reported either by the subject or determined by the dental evaluator.

    Time frame: End of treatment (3 weeks)

Secondary outcomes

  1. The Number of Participants With a Given Range of Average Oral Mucosal Sloughing Index Scores

    Average score based on the mean of sloughing scores over 12 intra-oral areas. The sloughing score uses a 6 point scale as follows: 0= no sloughing, 1=flecks of desquamation, 2=sheets of desquamation, 3=redness, not due to plaque, 4=erosion of mucosa, 5=ulcerated areas. The twelve intra-oral areas of the mouth are as follows: dorsal and ventral surfaces of the tongue, floor and roof of the mouth, right and left buccal mucosa, gingival tissue. (upper right, upper anterior, upper left, lower left, lower anterior, lower right)

    Time frame: Mid-Treatment (10 days)

  2. The Number of Participants With a Given Range of Average Oral Mucosal Sloughing Index Scores.

    Average score based on the mean of sloughing scores over 12 intra-oral areas. The sloughing score uses a 6 point scale as follows: 0= no sloughing, 1=flecks of desquamation, 2=sheets of desquamation, 3=redness, not due to plaque, 4=erosion of mucosa, 5=ulcerated areas. The twelve intra-oral areas of the mouth are as follows: dorsal and ventral surfaces of the tongue, floor and roof of the mouth, right and left buccal mucosa, gingival tissue. (upper right, upper anterior, upper left, lower left, lower anterior, lower right)

    Time frame: End of Treatment (3 weeks)

Other outcomes

  1. The Number of Participants Reporting Their Acceptance Levels of Side Effects

    Subjects were questioned regarding how acceptable were your side effects. Using the following responses of: Completely unacceptable, somewhat unacceptable, somewhat acceptable, completely acceptable, did not experience side effects

    Time frame: End of Treatment (3 weeks)

07

Results

Posted Nov 19, 2021
Limitations and caveats
The major limitation with this study is that the sample size goal was not reached given the early termination during the washout period of a two-period crossover design.

Participant flow

Participant flow — Overall Study
MilestoneComparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS Toothpaste
Started181817
Completed000
Not completed181817
Withdrew: Needed crown & cleaning001
Withdrew: Study was terminated181816

Outcome measures

PrimaryNumber of Participants With Oral Mucosal Exfoliation (Oral Sloughing)

Percentage of participants who experienced oral sloughing as reported either by the subject or determined by the dental evaluator.

Time frame:
End of treatment (3 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Oral Mucosal Exfoliation (Oral Sloughing)
ParticipantsComparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS Toothpaste
Number of Participants With Oral Mucosal Exfoliation (Oral Sloughing)151413
Statistical analysis
  • Comparator: No SLS Toothpaste vs Comparator: Medium SLS Toothpaste vs Comparator: High SLS Toothpaste · Fisher Exact · p = .916
SecondaryThe Number of Participants With a Given Range of Average Oral Mucosal Sloughing Index Scores

Average score based on the mean of sloughing scores over 12 intra-oral areas. The sloughing score uses a 6 point scale as follows: 0= no sloughing, 1=flecks of desquamation, 2=sheets of desquamation, 3=redness, not due to plaque, 4=erosion of mucosa, 5=ulcerated areas. The twelve intra-oral areas of the mouth are as follows: dorsal and ventral surfaces of the tongue, floor and roof of the mouth, right and left buccal mucosa, gingival tissue. (upper right, upper anterior, upper left, lower left, lower anterior, lower right)

Time frame:
Mid-Treatment (10 days)
Reported as:
Count of participants · Participants
The Number of Participants With a Given Range of Average Oral Mucosal Sloughing Index Scores
ParticipantsComparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS Toothpaste
0 no sloughing867
(0.0, 0.5]986
(0.5, 1.0]132
(1.0, 1.5]001
(1.5, 2.0]010
SecondaryThe Number of Participants With a Given Range of Average Oral Mucosal Sloughing Index Scores.

Average score based on the mean of sloughing scores over 12 intra-oral areas. The sloughing score uses a 6 point scale as follows: 0= no sloughing, 1=flecks of desquamation, 2=sheets of desquamation, 3=redness, not due to plaque, 4=erosion of mucosa, 5=ulcerated areas. The twelve intra-oral areas of the mouth are as follows: dorsal and ventral surfaces of the tongue, floor and roof of the mouth, right and left buccal mucosa, gingival tissue. (upper right, upper anterior, upper left, lower left, lower anterior, lower right)

Time frame:
End of Treatment (3 weeks)
Reported as:
Count of participants · Participants
The Number of Participants With a Given Range of Average Oral Mucosal Sloughing Index Scores.
ParticipantsComparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS Toothpaste
0 No sloughing697
(0.0, 0.5]966
(0.5, 1.0]322
(1.0, 1.5]011
Other pre-specifiedThe Number of Participants Reporting Their Acceptance Levels of Side Effects

Subjects were questioned regarding how acceptable were your side effects. Using the following responses of: Completely unacceptable, somewhat unacceptable, somewhat acceptable, completely acceptable, did not experience side effects

Time frame:
End of Treatment (3 weeks)
Reported as:
Count of participants · Participants
The Number of Participants Reporting Their Acceptance Levels of Side Effects
ParticipantsComparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS Toothpaste
Completely unacceptable212
Somewhat unacceptable201
Somewhat acceptable144
Completely acceptable143
Did not experience side effects1297

Adverse events

Collected over Within 3 weeks of starting treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Comparator: No SLS Toothpaste0/18 (0%)0/18 (0%)15/18 (83.3%)
Comparator: Medium SLS Toothpaste0/18 (0%)0/18 (0%)15/18 (83.3%)
Comparator: High SLS Toothpaste0/17 (0%)0/17 (0%)16/17 (94.1%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventComparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS Toothpaste
Oral mucosal exfoliationGastrointestinal disorders15/1814/1813/17
Dry mouthGastrointestinal disorders3/181/183/17
Hypoaesthesia oralGastrointestinal disorders1/181/182/17
DysgeusiaGastrointestinal disorders2/182/181/17
Mouth injuryGastrointestinal disorders0/182/181/17
Breath odorGastrointestinal disorders0/180/181/17
DyspepsiaGastrointestinal disorders0/180/181/17
GlossitisGastrointestinal disorders0/180/181/17
Oral discomfortGastrointestinal disorders1/180/181/17
Sensitivity of teethGastrointestinal disorders0/180/181/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Comparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS ToothpasteTotal
Mean43.2 ± 10.339.7 ± 12.0938.5 ± 11.8240.5 ± 11.38
Sex: Female, Male
Sex: Female, Male(Participants)Comparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS ToothpasteTotal
Female1111931
Male77822
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Comparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS ToothpasteTotal
Hispanic or Latino2013
Not Hispanic or Latino16181650
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Comparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS ToothpasteTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White18171752
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Comparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS ToothpasteTotal
United States18181753
Number of Participants with Oral Tissue Sloughing at Baseline
Number of Participants with Oral Tissue Sloughing at Baseline(Participants)Comparator: No SLS ToothpasteComparator: Medium SLS ToothpasteComparator: High SLS ToothpasteTotal
Count of participants0000
08

Study locations

1 site
  • 3M Health Care
    Saint Paul, Minnesota 55144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Mar 2020, 2 months.

Results were first posted in Nov 2021, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2020
First posted
Oct 23, 2020
StartActual
Jan 6, 2020
Primary completionActual
Mar 10, 2020
CompletionActual
Mar 10, 2020
Results first posted
Nov 19, 2021
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04601103
Lead sponsor
Solventum US LLC
Collaborators
3M
Responsible party
Sponsor
First posted
Oct 23, 2020
Start date
Jan 6, 2020
Primary completion
Mar 10, 2020
Completion
Mar 10, 2020
Results posted
Nov 19, 2021
Last update
Oct 1, 2024

Study contacts

Brenda C Coalwell, BA
principal investigator · 3M Health Care Business Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorophosphate

Start the discussion